Skip to content

Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma, sold RPRX on Jun 30, 2026

Data as of Oct 16

▼ SELL$1.7M29,400 shares at $56.44Christopher Hite EVP & Chairman, PartneringRPRX Royalty Pharma plc
Watch RPRX
Traded
Jun 30, 2026
Disclosed
Jul 2, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma, sold RPRX on Jun 30, 2026TRADEDDISCLOSED
RPRXSimilar stocks (XLV — its sector index fund), rebased to RPRX's price on the disclosure day
RPRX since disclosure
+5.5%
after the sale
Similar stocks (XLV) since disclosure
+7.9%
XLV — its sector index fund

Change in closing price from Jul 2, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLChristopher Hite EVP & Chairman, PartneringRPRX Royalty Pharma plc$146Kdisclosed Jul 2 · filed 2 days after the trade
  2. ▼ SELLChristopher Hite EVP & Chairman, PartneringRPRX Royalty Pharma plc$5.5Mdisclosed Jul 2 · filed 2 days after the trade
  3. ▼ SELLChristopher Hite EVP & Chairman, PartneringRPRX Royalty Pharma plc$34.3Kdisclosed Jul 2 · filed 2 days after the trade

See every trade on RPRX →